The MCCC considers the Developmental Funds as one of the most critical components of CCSG support. Together with institutionally derived MCCC discretionary funds and the annual grant support from the Fraternal Order of Eagles, these funds have supported recruitment of new research faculty, shared resource development, and the initiation of research projects or generation of pilot data for subsequent peer review grant applications. Given the small size of the CCSG Developmental Fund pool relative to the substantial expansion realized over the last funding period, institutionally-derived MCCC discretionary funds and philanthropic sources have contributed more than 90% of the funding needed for pilot projects, program or shared resource initiation, and all funding for instrumentation and new laboratory set-up costs. Processes are firmly established in the MCCC to solicit and review proposals for CCSG Developmental Fund support. Funding is predicated on scientific merit, programmatic relevance, MCCC strategic priorities and, in the case of shared resource development, the unambiguous need of peer review investigators. An increase in Developmental Funds is requested in this application, though it is commensurate with the funding level recommended for the current funding period (but not awarded). These Developmental Funds will be leveraged with institutionally derived MCCC discretionary funds. Funding is requested in the next project period to support initiatives in the following categories: ? Continued recruitment of outstanding new research faculty - the MCCC is currently actively recruiting to fill 20 positions across its three campuses ? Pilot projects - to enable the MCCC to pursue outstanding science leading to peer review funding; including highly innovative but high-risk proposals that might otherwise not receive funding ? Development of shared resources - to insure the scientific vitality of MCCC investigators and programs The MCCC's Developmental Fund request represents approximately 8% of the direct costs requested. The MCCC has a proven track record in stewardship of these funds as evidenced by the 'return on investment'of new faculty recruited to the center during the current grant period. The current request, substantially buttressed by the continued commitment of MCCC discretionary funds, will enable the Director to support activities critical to the sustained research excellence of this Cancer Center.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA015083-39
Application #
8465650
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-03-01
Budget End
2014-02-28
Support Year
39
Fiscal Year
2013
Total Cost
$330,609
Indirect Cost
$101,734
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Wallace, Sumer K; Halverson, Jessica W; Jankowski, Christopher J et al. (2018) Optimizing Blood Transfusion Practices Through Bundled Intervention Implementation in Patients With Gynecologic Cancer Undergoing Laparotomy. Obstet Gynecol 131:891-898
Shrestha, Shikshya; Zhang, Cheng; Jerde, Calvin R et al. (2018) Gene-Specific Variant Classifier (DPYD-Varifier) to Identify Deleterious Alleles of Dihydropyrimidine Dehydrogenase. Clin Pharmacol Ther 104:709-718
Hu, G; Dasari, S; Asmann, Y W et al. (2018) Targetable fusions of the FRK tyrosine kinase in ALK-negative anaplastic large cell lymphoma. Leukemia 32:565-569
Geller, James I; Fox, Elizabeth; Turpin, Brian K et al. (2018) A study of axitinib, a VEGF receptor tyrosine kinase inhibitor, in children and adolescents with recurrent or refractory solid tumors: A Children's Oncology Group phase 1 and pilot consortium trial (ADVL1315). Cancer 124:4548-4555
Luchtel, Rebecca A; Dasari, Surendra; Oishi, Naoki et al. (2018) Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements. Blood 132:1386-1398
Oishi, Naoki; Brody, Garry S; Ketterling, Rhett P et al. (2018) Genetic subtyping of breast implant-associated anaplastic large cell lymphoma. Blood 132:544-547
DuBois, Steven G; Mosse, Yael P; Fox, Elizabeth et al. (2018) Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma. Clin Cancer Res 24:6142-6149
Farber, Benjamin A; Lalazar, Gadi; Simon, Elana P et al. (2018) Non coding RNA analysis in fibrolamellar hepatocellular carcinoma. Oncotarget 9:10211-10227
Lu, Yingchang; Beeghly-Fadiel, Alicia; Wu, Lang et al. (2018) A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. Cancer Res 78:5419-5430
Dasari, Surendra; Newsom, Sean A; Ehrlicher, Sarah E et al. (2018) Remodeling of skeletal muscle mitochondrial proteome with high-fat diet involves greater changes to ?-oxidation than electron transfer proteins in mice. Am J Physiol Endocrinol Metab 315:E425-E434

Showing the most recent 10 out of 1129 publications